Enhertu is already FDA-approved for some patients with advanced gastric cancer and is being tested for its benefits in other tumor types.

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer, including a 44% improvement in progression-free ...

Not only is this set to fulfill the desire of a Nintendo DS experience (which, if it wasn't clear already, DS stands for Dual Screen), but it's also intent on providing an OLED visual experience ...

DESTINY-Lung04 phase 3 trial of Enhertu initiated in patients with previously untreated HER2 mutant metastatic non-small cell lung cancer. News release. Daiichi Sankyo. December 23, 2021.

Lea is hopeful about the potential effectiveness of Enhertu on her brain cancer because it has the rare ability to cross the blood-brain barrier, unlike many chemotherapies.

The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

Portal Biotech announced a $35 million Series A raise, representing one of Europe's largest investments into a life sciences tools company.

See the latest AstraZeneca PLC ADR stock price (AZN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

DATROWAY ® has been approved in the US for the treatment of adult patients with locally advanced or metastatic EGFR- mutated non-small cell lung cancer who have received prior EGFR- directed ...

But she believes it could potentially be effective for her brain cancer too, because Enhertu crosses the blood-brain barrier – which not many chemotherapies do.